MedTrace Logo

Integrating Buprenorphine Into HIV Treatment

NCT00241930 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2005-10-25

No results posted yet for this study

Summary

We hypothesize that integrating drug treatment into HIV treatment will improve HIV outcomes as well as drug treatment outcomes in heroin users. This study will test this hypothesis by randomizing patients to two groups. The first group will receive HIV treatment and buprenorphine treatment contemporaneously at their HIV clinic. The second group will receive HIV treatment at their HIV clinic, and go to another facility to receive buprenorphine treatment services.

We will look at HIV outcomes such as CD4 counts, HIV viral loads, and attendance at appointments and drug treatment outcomes such as receipt of buprenorphine and urine toxicology testing.

Conditions

  • Opiate Dependence
  • HIV Infections

Interventions

BEHAVIORAL

Integrating drug treatment into HIV services

Sponsors & Collaborators

  • Organization to Achieve Solutions in Substance Abuse (OASIS)

    lead OTHER

Principal Investigators

  • Diana L Sylvestre, MD · Organization to Achieve Solutions in Substance Abuse (OASIS)

  • Ruth Finkelstein, ScD · New York Academy of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00241930 on ClinicalTrials.gov